Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

BACKGROUND: The risk of severe COVID-19 outcomes in people with immune-mediated inflammatory diseases and on immune-modifying drugs might not be fully mediated by comorbidities and might vary by factors such as ethnicity. We aimed to assess the risk of severe COVID-19 in adults with immune-mediated...

Descripción completa

Detalles Bibliográficos
Autores principales: MacKenna, Brian, Kennedy, Nicholas A, Mehrkar, Amir, Rowan, Anna, Galloway, James, Matthewman, Julian, Mansfield, Kathryn E, Bechman, Katie, Yates, Mark, Brown, Jeremy, Schultze, Anna, Norton, Sam, Walker, Alex J, Morton, Caroline E, Harrison, David, Bhaskaran, Krishnan, Rentsch, Christopher T, Williamson, Elizabeth, Croker, Richard, Bacon, Seb, Hickman, George, Ward, Tom, Davy, Simon, Green, Amelia, Fisher, Louis, Hulme, William, Bates, Chris, Curtis, Helen J, Tazare, John, Eggo, Rosalind M, Evans, David, Inglesby, Peter, Cockburn, Jonathan, McDonald, Helen I, Tomlinson, Laurie A, Mathur, Rohini, Wong, Angel Y S, Forbes, Harriet, Parry, John, Hester, Frank, Harper, Sam, Douglas, Ian J, Smeeth, Liam, Lees, Charlie W, Evans, Stephen J W, Goldacre, Ben, Smith, Catherine H, Langan, Sinéad M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179144/
https://www.ncbi.nlm.nih.gov/pubmed/35698725
http://dx.doi.org/10.1016/S2665-9913(22)00098-4

Ejemplares similares

Ejemplares similares